Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma

Cardio-Oncology

Michael G. Fradley¹  Cynthia Courtney²  Gary J. Schiller²  Eric H. Yang³  Vinisha Garg³ 

[1] Cardio-oncology Program, Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine and H. Lee Moffitt Cancer Center and Research Institute;Division of Hematology and Oncology, David Geffen School of Medicine at UCLA;UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine UCLA Cardiovascular Center;

关键词: Carfilzomib;    Proteasome inhibitors;    Multiple myeloma;    Heart failure;    Cardiac biomarkers;   

DOI  :  10.1186/s40959-018-0028-z

来源: DOAJ

【 摘 要 】

Abstract Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM). However, there are reports of adverse cardiac events with carfilzomib manifested by dyspnea and heart failure. A patient is presented who had recurrent, clinically mild cardiotoxicity, as manifested by recurrent heart failure with preserved ejection fraction, with ongoing maintenance carfilzomib in a patient with resistant MM is presented.

【 授权许可】

Unknown